Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
An erratum to this article was published (Diabetes Obes Metab, 20 Oct 2026 ↗)
Authors' conclusion
The proportion of participants achieving anthropometric targets was greater with CagriSema Versus other treatments.
Study context
- Population
- Adults without diabetes with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with ≥ 1 obesity-related complication
- Comparison
- Once-weekly CagriSema vs semaglutide vs cagrilintide vs placebo, plus lifestyle intervention
- Primary endpoint
- Proportions of participants achieving BMI < 27 kg/m² and/or WHtR < 0.53 targets
- Follow-up
- Week 68
Methodological detailsphase 3a, 68-week
- Phase 3a
- 68-week
Primary result
As reported in the abstract
Achieving both BMI < 27 kg/m² and WHtR < 0.53 targets
Further findings
- Both BMI and WHtR performed similarly as indicators for all four cardiometabolic outcomes
- At more stringent cut-off values, anthropometric targets were better measures than percentage weight loss
Original publication
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. Diabetes Obes Metab. Published 26 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →